LEUKEMIAS

The second-generation T-cell immunotherapy Orca-Q demonstrated encouraging outcomes in an ongoing phase 1 trial.

FDA designates TERN-701 as breakthrough therapy for heavily pretreated Ph+ CP-CML, as allosteric BCR-ABL inhibitor shows rapid deep molecular responses and tolerable safety.

Longer follow-up from the NMDP's ACCESS trial emphasizes the opportunity to use mismatched stem cell donors in more diverse patient populations.

UK trial data show TP53 and unmutated IGHV outperform copy-number complexity for CLL prognosis, guiding smarter molecular risk stratification.

Explore 2026 CLL frontline choices, from all-oral acalabrutinib–venetoclax to MRD-guided care, plus pipeline advances and Richter’s strategies.

New CMML molecular framework links genomic classes and iCPSS scoring to predict outcomes and guide optimal stem cell transplant timing.

During a live event, Catherine Coombs, MD and participants explored fixed-duration frontline CLL therapies, focusing on patient selection, data gaps, and trade-offs.

The FDA has extended the deadline to review Orca-T for the treatment of myelodsyplastic syndromes and acute leukemias with a PDUFA date of July 6, 2026.

ABC trial interim results demonstrate effective, short-duration prophylaxis without conventional immunosuppressants and with dose-reduced cyclophosphamide.

Ten-year trial shows CD22 CAR T drives deep remissions in relapsed pediatric B-ALL, with transplant boosting durability and manageable toxicity.

Post-transplant gilteritinib maintenance may boost survival and reduce relapse in relapsed FLT3-mutated AML, though larger trials are still needed.

Real-world brexu-cel CAR-T data in adult R/R B-ALL show trial-like ICANS, CRS, and highlight monitoring and risk factors.

During a live event, Catherine Coombs, MD and participants debate frontline CLL BTK inhibitors: who benefits from continuous therapy, acalabrutinib vs zanubrutinib nuances, and pirtobrutinib's future role.

New trial data suggest azacitidine-venetoclax may rival 7+3 in AML, shifting induction toward targeted, less toxic combinations.

Modeling shows zanubrutinib may cut progression and costs versus acalabrutinib in relapsed/refractory CLL, especially in high-risk patients.

Cross-trial analysis shows zanubrutinib delivers longer progression-free survival than ibrutinib or acalabrutinib in relapsed CLL, including high-risk del(17p)/del(11q).

FDA approves 14‑month, all‑oral acalabrutinib plus venetoclax first-line for CLL/SLL, boosting progression-free survival and offering a fixed-duration alternative to chemo.

Early trial shows subcutaneous blinatumomab drives remission in rare MPAL, enabling simpler community care and wider access.

ASH updates AYA ALL care: pediatric-inspired frontline therapy, MRD-driven decisions, targeted TKIs, and immunotherapy-led relapse treatment.

BTK inhibitors or time-limited venetoclax combos? Expert breaks down CLL frontline choices, IGHV and p53 risk, and what fits patient life.

G6PD deficiency links to higher remission and longer survival in AML patients on venetoclax plus azacitidine, suggesting a simple biomarker to guide treatment.

CD34+ donor chimerism flags AML relapse early; timely donor lymphocyte infusion boosts MRD-negative remissions and survival after alloHSCT.

Phase 2 data show varnim-cel delivers 83% responses with mostly mild CRS and minimal neurotoxicity, boosting CAR T access in India.

FDA fast-tracks QTX-2101, an oral arsenic trioxide therapy, enhancing treatment accessibility for acute promyelocytic leukemia patients.

FDA grants orphan drug designation to CTD402, a promising CAR T therapy for relapsed T-cell leukemia and lymphoma, enhancing treatment accessibility.